Bavencio and gemcitabine show efficacy in advanced leiomyosarcoma, with a 20% objective response rate and 71% disease control rate. Higher TIL density correlates with improved objective response rates ...
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)
FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study Uterine leiomyosarcoma (uLMS) is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results